Antisense oligonucleotides in the treatment of cancer

Antisense and Nucleic Acid Drug Development

Volumn 9, Issue 4, 1999, Pages 391-396

  Andrew Dorr, F ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000532453     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. BISHOP, J.M. (1987). The molecular genetics of cancer. Science 235, 3005-3006.
2. BOS, J.L. (1989). ras oncogene in human cancer: A review. Cancer Res. 49, 4682-4689.
3. COWSERT, L.M. (1997). In vitro and in vivo activity of antisense inhibitors of ras: Potential for clinical development. Anti-Cancer Drug Design 12, 359-371.
4. DAUM, G., EISENMANN-TAPP, I., FRIES, H.-W., TROPPMAIR, J.,and RAPP, U.R. (1994). The ins and outs of Raf kinases. TIBS 19, 474-480.
5. DEAN, N.M., McKAY, R., MIRAGLIA, L., GEIGERT, T., MULLERT, M., FABBRO, D.,and BENNETT, C.F. (1996). Antisense oligonucleotides as inhibitors of signal transduction: Development from research tools to therapeutic agents. Biochem. Soc. Trans. 24, 623-629.
6. HENRY, S.P., MONTEITH, D., BENNETT, F.,and LEVIN, A.A. (1997). Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and Cra/kinase. Anti-Cancer Drug Design 12, 409-420.
7. HOLMLUND, J., NEMUNAITIS, J., SCHILLER, J., DORR, A.,and K1SNER, D. (1998). Phase I trial of C-raf antisense oligonucleotide ISIS 5132 (CGP 69846A) by 21-day continuous intravenous infusion (CIV) in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. 17, 210a (abstract 811).
8. HOWE, L.R., LEEVERS, S.J., GOMEZ, N., NAKIELNY, S., COHEN, P.,and MARSHALL, C.I. (1992). Activation of the MAP kinase pathway by the protein kinase raf. Cell 71, 335-342.
9. LACAL, J.C.,and TRONICK, S.R. (1988). The ras oncogene. In: The Oncogene Handbook. E.P. Reddy and T. Curran, eds. (Eisevier Science, Amsterdam), pp. 257-292.
10. MONIA, B.P., JOHNSTON, J.F., GEIGER, T., FREIER, S.M., LESNIK, E.A., MULLER, M., GEIGER, T., ALTMANN, K.-H., MOSER, H.,and FABBRO, D. (1996a). Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against Cra/kinase. Nature Med. 2, 668-675.
11. MONIA, B.P., SASMOR, H., JOHNSTON, J.F., MULLER, M.,and FABBRO, D. (1996b). Sequence-specific activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc. Natl. Acad. Sci. USA 93, 15481-15484.
12. NEMUNAITIS, J., HOLMLUND, J.T., KRAYNAK, M., RICHARDS, D., BRUCE, J., OGNOSKffi, N., KWOH, T.J., GEARY, R., DORR, A., VON HOFF, D.,and ECKHARDT, S.O. (1999). Phase I evaluation of ISIS 3521 (ISI 641A), an antisense oligodeoxynucleotide to protein kinase C-a, in patients with advanced cancer. J. Clin. Oncol. In press.
13. NISHIZUKA, Y. (1992). Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258, 607-614.
14. O'DWYER, P.J., STEVENSON, J.P., GALLAGHER, M., MITCHEL, E., FRIEDLAND, D., ROSE, L., CASSELLA, A., HOLMLUND, J., DEAN, N., DOOR, A., GERY, R.,and YAO, K.-S. (1998). Phase I/Pharrnacokinetic/pharmacodynamic trial of raf-1 antisense ODN (ISIS 5132, CGP 69846A). Proc. ASCO 17, 210a, abstract 810.
15. RAPP, U.R. (1991). Role of Raf-1 serine/threonine protein kinase in growth factor signal transduction. Oncogene 6, 495-500.
16. SIKIC, B.I., YUEN, A.R., ADV AMI, R., HALSEY, J., FISHER, G.A., HOLMLUND, J.,and DORR, A. (1998). Antisense oligonucleotide therapy targeted to protein kinase C-a (ISIS 3521/CGP 64128A) by 21-day infusion: Results of the phase I trial and activity in ovarian carcinomas. Proc. ASCO 17, 429a, abstract 1654.
17. STEVENSON, J.P., YAO, K.-S., GALLAGHER, M., FRIEDLAND, D., MITCHELL, E.P., CASSELLA, A., MON1A, B., YU, R., HOLMLUND, J., DORR, F.A.,and O'DWYER, PJ. (1999). Phase I clinical/pharmacokinetic and pharmacodynamic trial of the C-ra/-l antisense oligonucleotide ISIS 5132 (CGP 69846A). J. Clin. Oncol. 17, 2237-2243.
18. WANG, H.G., MIYASHITA, T., TAKAYAMA, S., SATO, T., TORIGOE, T., KRAJEWSKI, S., TANAKA, S., HOVEY, L. ID, TROPPMAIR, J.,and RAPP, UR. (1994). Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase. Oncogene 9, 2751-2756.